Atyr Pharma Inc (LIFE): Paul Schimmel , director of Atyr Pharma Inc purchased 85,000 shares on Apr 8, 2016. The Insider buying transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.22 per share for a total value of $273,649.00.
Currently the company Insiders own 2.6% of aTyr Pharma Inc shares according to the proxy statements.Institutional Investors own 61.36% of aTyr Pharma Inc shares.
aTyr Pharma Inc: On Monday, Apr 11, 2016 heightened volatility was witnessed in aTyr Pharma Inc which led to swings in the share price. The shares opened for trading at $3.34 and hit $3.68 on the upside , eventually ending the session at $3.62, with a gain of 13.13% or 0.42 points. The heightened volatility saw the trading volume jump to 23,23,299 shares. The 52-week high of the share price is $28.29 and the company has a market cap of $86 M . The 52-week low of the share price is at $3.03.
aTyr Pharma Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines a class of naturally occurring proteins that promotes homeostasis. The Companys Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction including severe diseases of the lung gut skin brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.